Joe Y Chang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6431889/publications.pdf

Version: 2024-02-01

222 papers	14,345 citations	19657 61 h-index	23533 111 g-index
265 all docs	265 docs citations	265 times ranked	10548 citing authors

#	Article	IF	Citations
1	Monte Carlo evaluation of target dose coverage in lung stereotactic body radiation therapy with flattening filter-free beams. Journal of Radiotherapy in Practice, 2022, 21, 81-87.	0.5	1
2	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 361-375.	0.8	22
3	An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a â€œno-treat zoneâ€. Radiation Oncology, 2022, 17, 4.	2.7	1
4	Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers. JAMA Oncology, 2022, 8, 333.	7.1	2
5	AAPM Task Group Report 290: Respiratory motion management for particle therapy. Medical Physics, 2022, 49, .	3.0	30
6	Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2022, 114, 635-644.	0.8	18
7	Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Lancet Oncology, The, 2022, 23, e156.	10.7	9
8	Clinical necessity of multi-image based (4DMIB) optimization for targets affected by respiratory motion and treated with scanned particle therapy â€“ A comprehensive review. Radiotherapy and Oncology, 2022, 169, 77-85.	0.6	12
9	Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta OncolÃ³gica, 2022, 61, 403-408.	1.8	6
10	Optimize Local Therapy for Oligometastatic and Oligoprogressive Nonâ€“Small Cell Lung Cancer to Enhance Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 531-539.	4.9	10
11	Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Scientific Reports, 2022, 12, .	3.3	4
12	Alleviating breathlessness in patients with cancer with dexamethasone (ABCD): A parallel-group, double-blind, randomized clinical trial (RCT).. Journal of Clinical Oncology, 2022, 40, 12112-12112.	1.6	0
13	Using FFF beams to improve the therapeutic ratio of lung SBRT. Journal of Radiotherapy in Practice, 2021, 20, 419-425.	0.5	5
14	Use of Multi-Site Radiation Therapy for Systemic Disease Control. International Journal of Radiation Oncology Biology Physics, 2021, 109, 352-364.	0.8	34
15	Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clinical Lung Cancer, 2021, 22, 225-233.e7.	2.6	2
16	American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology, 2021, 16, 54-65.	1.1	13
17	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respiratory Medicine,the, 2021, 9, 467-475.	10.7	277
18	When Constrained by Constraints: Thinking Outside of the Box in Both Technology and Biology. International Journal of Radiation Oncology Biology Physics, 2021, 110, 266-267.	0.8	5

#	Article	IF	Citations
19	Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology, 2021, 16, 269-277.	1.1	23
20	American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. Journal of Thoracic Oncology, 2021, 16, 66-75.	1.1	17
21	Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era?. Translational Lung Cancer Research, 2021, 10, 5-8.	2.8	1
22	Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial. Investigational New Drugs, 2021, 39, 1113-1122.	2.6	3
23	Consensus Statement on Proton Therapy in Mesothelioma. Practical Radiation Oncology, 2021, 11, 119-133.	2.1	11
24	Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clinical and Translational Radiation Oncology, 2021, 28, 54-61.	1.7	5
25	Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial.. Journal of Clinical Oncology, 2021, 39, 8506-8506.	1.6	7
26	Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 805-813.	4.9	2
27	Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Seminars in Radiation Oncology, 2021, 31, 217-226.	2.2	2
28	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Nonâ€“Small Cell Lung Cancer and Poor Performance Status. JAMA Oncology, 2021, 7, 1497.	7.1	45
29	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiotherapy and Oncology, 2021, 162, 60-67.	0.6	45
30	Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e745-e755.	2.6	15
31	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncology, The, 2021, 22, 1448-1457.	10.7	154
32	Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. Radiotherapy and Oncology, 2021, 163, 114-118.	0.6	12
33	Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. Frontiers in Oncology, 2021, 11, 748331.	2.8	4
34	SABR for operable stage I non-small-cell lung cancer: comparison to surgery â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e537-e538.	10.7	0
35	Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 266-273.	1.1	58
36	Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. International Journal of Radiation Oncology Biology Physics, 2020, 106, 90-99.	0.8	24

#	Article	IF	Citations
37	Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. Journal of Thoracic Oncology, 2020, 15, 101-109.	1.1	38
38	Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. Journal of Thoracic Oncology, 2020, 15, 176-189.	1.1	29
39	Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 100-107.	0.8	15
40	Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Practical Radiation Oncology, 2020, 10, 324-329.	2.1	11
41	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. Journal of Thoracic Oncology, 2020, 15, 248-257.	1.1	97
42	Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. Journal of Thoracic Oncology, 2020, 15, 1919-1927.	1.1	53
43	Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. , 2020, 8, e001001.		143
44	American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2020, 108, E48-E49.	0.8	9
45	Metabolic Responses to Metformin in Inoperable Early-stage Nonâ€“Small Cell Lung Cancer Treated With Stereotactic Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 231-235.	1.3	17
46	Clinical and Radiographic Presentations of COVID-19 Among Patients Receiving Radiation Therapy for Thoracic Malignancies. Advances in Radiation Oncology, 2020, 5, 700-704.	1.2	9
47	Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Seminars in Radiation Oncology, 2020, 30, 253-261.	2.2	18
48	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. Journal of Clinical Oncology, 2020, 38, 1569-1579.	1.6	158
49	Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study. Frontiers in Oncology, 2020, 10, 12.	2.8	11
50	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head and Neck, 2020, 42, 1939-1953.	2.0	29
51	Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. International Journal of Radiation Oncology Biology Physics, 2020, 107, 897-908.	0.8	2
52	An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer. Radiotherapy and Oncology, 2020, 145, 209-214.	0.6	3
53	Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 261-269.	0.8	5
54	Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e203277.	5.9	15

#	Article	IF	Citations
55	Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. Journal of Thoracic Oncology, 2020, 15, 1085-1087.	1.1	15
56	Lymanâ€“Kutcherâ€“Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiotherapy and Oncology, 2020, 146, 200-204.	0.6	12
57	Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC?. Frontiers in Oncology, 2019, 9, 551.	2.8	3
58	Proton therapy for non-small cell lung cancer: the road ahead. Translational Lung Cancer Research, 2019, 8, S202-S212.	2.8	15
59	Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions. Translational Lung Cancer Research, 2019, 8, 524-531.	2.8	9
60	Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncology, 2019, 5, 1597.	7.1	53
61	Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e480-e488.	2.6	2
62	Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Molecular Cancer, 2019, 18, 21.	19.2	104
63	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Frontiers in Immunology, 2019, 10, 193.	4.8	105
64	Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. Journal of Immunotherapy, 2019, 42, 55-64.	2.4	34
65	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiationâ€“Related Abscopal Responses. Cancer Immunology Research, 2019, 7, 1903-1909.	3.4	86
66	Time to abandon single-site irradiation for inducing abscopal effects. Nature Reviews Clinical Oncology, 2019, 16, 123-135.	27.6	233
67	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Scientific Reports, 2018, 8, 1922.	3.3	108
68	Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1090-1097.	0.8	56
69	Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. Advances in Radiation Oncology, 2018, 3, 139-145.	1.2	2
70	Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 558-563.	0.8	55
71	Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 479-489.	0.8	44
72	Reirradiation of thoracic cancers with intensity modulated proton therapy. Practical Radiation Oncology, 2018, 8, 58-65.	2.1	34

#	Article	IF	Citations
73	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 21-24.	1.4	1
74	Combining radiation plus immunotherapy to improve systemic immune response. Journal of Thoracic Disease, 2018, 10, S468-S479.	1.4	46
75	Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy. Journal of Thoracic Disease, 2018, 10, S1124-S1126.	1.4	4
76	Proton therapy for early-stage non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2018, 7, 199-204.	2.8	8
77	How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. Journal of Thoracic Disease, 2018, 10, 3883-3890.	1.4	2
78	Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy. Translational Lung Cancer Research, 2018, 7, S280-S282.	2.8	3
79	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. , 2018, 6, 128.		233
80	Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Network Open, 2018, 1, e181390.	5.9	48
81	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Antiâ€“PD1-Resistant Lung Tumor Model. Clinical Cancer Research, 2018, 24, 5735-5743.	7.0	48
82	In Reply to Hurmuz and Ozyigit. International Journal of Radiation Oncology Biology Physics, 2018, 101, 745.	0.8	0
83	Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients. Journal of Cancer, 2018, 9, 584-593.	2.5	29
84	Accounting for, Mitigating, and Choice of Margins for Moving Tumors. Seminars in Radiation Oncology, 2018, 28, 194-200.	2.2	4
85	Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.. Journal of Clinical Oncology, 2018, 36, TPS8580-TPS8580.	1.6	4
86	Trends and Outcomes of Proton Radiation Therapy Use for Nonâ€“Small Cell Lung Cancer. International Journal of Particle Therapy, 2018, 5, 18-27.	1.8	2
87	Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiotherapy and Oncology, 2017, 122, 274-280.	0.6	38
88	Long-Term Outcomes of Salvage Stereotactic AblativeÂRadiotherapy for Isolated Lung Recurrence of Nonâ€“Small Cell Lung Cancer: A Phase II Clinical Trial. Journal of Thoracic Oncology, 2017, 12, 983-992.	1.1	51
89	7â€year followâ€up after stereotactic ablative radiotherapy for patients with stage I nonâ€“small cell lung cancer: Results of a phase 2 clinical trial. Cancer, 2017, 123, 3031-3039.	4.1	125
90	Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 900-907.	0.8	37

#	Article	IF	Citations
91	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative BodyÂRadiotherapy Patients. Annals of Thoracic Surgery, 2017, 103, 1600-1605.	1.3	37
92	Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiotherapy and Oncology, 2017, 125, 325-330.	0.6	0
93	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2017, 3, e172032.	7.1	119
94	Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 667-676.	0.8	79
95	Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. International Journal of Radiation Oncology Biology Physics, 2017, 99, 41-50.	0.8	162
96	Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. Journal of Thoracic Oncology, 2017, 12, 375-382.	1.1	58
97	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Research, 2017, 77, 839-850.	0.9	195
98	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research, 2017, 23, 1388-1396.	7.0	261
99	Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Practical Radiation Oncology, 2017, 7, e195-e203.	2.1	44
100	Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Practical Radiation Oncology, 2017, 7, 63-71.	2.1	8
101	Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer. Journal of Thoracic Disease, 2016, 8, 1394-1397.	1.4	3
102	PD-L1 expression in lung cancer. Journal of Thoracic Disease, 2016, 8, 3053-3055.	1.4	2
103	Is surgery still the optimal treatment for stage I non-small cell lung cancer?. Translational Lung Cancer Research, 2016, 5, 183-189.	2.8	22
104	Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. Cancers, 2016, 8, 23.	3.7	13
105	MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Nonâ€“Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0150467.	2.5	7
106	A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Scientific Reports, 2016, 6, 24364.	3.3	29
107	Motionâ€robust intensityâ€modulated proton therapy for distal esophageal cancer. Medical Physics, 2016, 43, 1111-1118.	3.0	63
108	Prospective Study of Patient-Reported Symptom Burden in Patients With Nonâ€“Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management, 2016, 51, 832-838.	1.2	27

#	Article	IF	Citations
109	Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1226-1235.	0.8	56
110	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer Journal (Sudbury, Mass), 2016, 22, 257-266.	2.0	38
111	Consensus Statement on Proton Therapy inÂEarly-Stage and Locally Advanced Nonâ€“Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 505-516.	0.8	125
112	Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2016, 17, e42-e43.	10.7	2
113	Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. Nature Reviews Clinical Oncology, 2016, 13, 516-524.	27.6	288
114	Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 523-533.	0.8	103
115	Novel Hybrid Scattering- and Scanning-Beam Proton Therapy Approach. International Journal of Particle Therapy, 2016, 3, 37-50.	1.8	2
116	MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget, 2016, 7, 84688-84694.	1.8	12
117	Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Oncotarget, 2016, 7, 7773-7779.	1.8	27
118	Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report. Oncotarget, 2016, 7, 13265-13268.	1.8	7
119	Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. Oncotarget, 2016, 7, 48842-48849.	1.8	9
120	Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Nonâ€“Small-Cell Lung Cancer: What We Have Learned. Journal of Thoracic Oncology, 2015, 10, 577-585.	1.1	133
121	Radiation with immunotherapy: an emerging combination for cancer treatment. Journal of Radiation Oncology, 2015, 4, 331-338.	0.7	5
122	The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treatment Reviews, 2015, 41, 503-510.	7.7	482
123	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Molecular Therapy - Nucleic Acids, 2015, 4, e270.	5.1	63
124	Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Nonâ€“Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation. Clinical Lung Cancer, 2015, 16, 156-163.	2.6	31
125	Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiotherapy and Oncology, 2015, 114, 367-372.	0.6	72
126	Surgery versus SABR for resectable non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e374-e375.	10.7	10

#	Article	IF	Citations
127	Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. Practical Radiation Oncology, 2015, 5, e383-e391.	2.1	22
128	Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage IIâ€“III inoperable non-small cell lung cancer. Radiotherapy and Oncology, 2015, 115, 367-372.	0.6	82
129	Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Lung Cancer. Seminars in Radiation Oncology, 2015, 25, 110-116.	2.2	32
130	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncology, The, 2015, 16, 630-637.	10.7	1,220
131	A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). International Journal of Radiation Oncology Biology Physics, 2015, 93, 757-764.	0.8	317
132	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	2.0	83
133	Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 91, 149-156.	0.8	52
134	Charged Particles in Stereotactic Radiosurgery. , 2015, , 135-146.		1
135	Stereotactic ablative radiotherapy: aim for a cure of cancer. Annals of Translational Medicine, 2015, 3, 12.	1.7	4
136	Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer. Drug Design, Development and Therapy, 2014, 8, 667.	4.3	11
137	Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy for Early-Stage Nonâ€“Small Cell Lung Cancers in the Elderly. JAMA Surgery, 2014, 149, 1244.	4.3	227
138	Proton-Based Stereotactic Ablative Radiotherapy in Early-Stage Non-Small-Cell Lung Cancer. BioMed Research International, 2014, 2014, 1-7.	1.9	10
139	Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Practical Radiation Oncology, 2014, 4, e259-e268.	2.1	56
140	Stereotactic ablative radiotherapy (SABR) using 70Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiotherapy and Oncology, 2014, 112, 256-261.	0.6	78
141	Clinical Implementation of Intensity Modulated Proton Therapy for Thoracic Malignancies. International Journal of Radiation Oncology Biology Physics, 2014, 90, 809-818.	0.8	125
142	Definitive Reirradiation for Locoregionally Recurrent Non-Small Cell Lung Cancer With Proton Beam Therapy or Intensity Modulated Radiation Therapy: Predictors of High-Grade Toxicity and Survival Outcomes. International Journal of Radiation Oncology Biology Physics, 2014, 90, 819-827.	0.8	71
143	In Reply to Oskan. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1142.	0.8	0
144	On the interplay effects with proton scanning beams in stage III lung cancer. Medical Physics, 2014, 41, 021721.	3.0	87

#	Article	IF	Citations
145	In Regard to Vanderstraeten etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 90, 238.	0.8	2
146	Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial. Radiation Oncology, 2014, 9, 108.	2.7	10
147	Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer: How to Fly in a â€œNo Fly Zoneâ€. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1120-1128.	0.8	225
148	Evaluation of the systematic error in using 3D dose calculation in scanning beam proton therapy for lung cancer. Journal of Applied Clinical Medical Physics, 2014, 15, 47-56.	1.9	11
149	Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. Journal of Thoracic Disease, 2014, 6, 348-55.	1.4	7
150	Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. Journal of Thoracic Disease, 2014, 6, 285-6.	1.4	2
151	Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiotherapy and Oncology, 2013, 109, 82-88.	0.6	42
152	Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Medical Dosimetry, 2013, 38, 442-447.	0.9	19
153	Can Stereotactic Ablative Radiotherapy in Early Stage Lung Cancers Produce Comparable Success as Surgery?. Thoracic Surgery Clinics, 2013, 23, 369-381.	1.0	18
154	Clinical Controversies: Proton Therapy for Thoracic Tumors. Seminars in Radiation Oncology, 2013, 23, 115-119.	2.2	17
155	New weighted maximumâ€intensityâ€projection images from cine CT for delineation of the lung tumor plus motion. Medical Physics, 2013, 40, 061901.	3.0	5
156	Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities. Lung Cancer, 2013, 82, 252-259.	2.0	61
157	Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiotherapy and Oncology, 2013, 109, 38-44.	0.6	66
158	Oncology Scanâ€”Promising Strategies for the Treatment of Locally-Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1-4.	0.8	14
159	Comparison of 2 Common Radiation Therapy Techniques for Definitive Treatment of Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 139-147.	0.8	36
160	Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer. Cancer, 2013, 119, 3402-3410.	4.1	75
161	Phase 1 Study of Dose Escalation in Hypofractionated Proton Beam Therapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 665-670.	0.8	51
162	Evolution of modern-era radiotherapy strategies for unresectable advanced non-small-cell lung cancer. Lung Cancer Management, 2013, 2, 213-225.	1.5	2

#	Article	IF	Citations
163	Therapy-Resistant Cancer Stem Cells Have Differing Sensitivity to Photon versus Proton Beam Radiation. Journal of Thoracic Oncology, 2013, 8, 1484-1491.	1.1	55
164	Capsular contracture of subcutaneous breast implant following hypofractionated stereotactic body radiotherapy for early stage lung cancer. Journal of Radiosurgery and SBRT, 2013, 2, 165-170.	0.2	0
165	Primary Lung Cancer. Medical Radiology, 2012, , 137-162.	0.1	2
166	Positron Emission Tomography/Computed Tomography-Guided Intensity-Modulated Radiotherapy for Limited-Stage Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e91-e97.	0.8	62
167	Positron Emission Tomography for Assessing Local Failure After Stereotactic Body Radiotherapy for Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1558-1565.	0.8	86
168	Automated Volumetric Modulated Arc Therapy Treatment Planning for Stage III Lung Cancer: How Does It Compare With Intensity-Modulated Radio Therapy?. International Journal of Radiation Oncology Biology Physics, 2012, 84, e69-e76.	0.8	48
169	Predicting Radiation Pneumonitis After Stereotactic Ablative Radiation Therapy in Patients Previously Treated With Conventional Thoracic Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1017-1023.	0.8	87
170	Adaptive/Nonadaptive Proton Radiation Planning and Outcomes in a Phase II Trial for Locally Advanced Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1093-1100.	0.8	70
171	Comparative Effectiveness of 5 Treatment Strategies for Early-Stage Non-Small Cell Lung Cancer in the Elderly. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1060-1070.	0.8	246
172	Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus. Practical Radiation Oncology, 2012, 2, 41-45.	2.1	11
173	Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiotherapy and Oncology, 2012, 105, 250-257.	0.6	15
174	Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiation Oncology, 2012, 7, 152.	2.7	124
175	FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiation Oncology, 2012, 7, 144.	2.7	22
176	Proton therapy for nonâ€“small cell lung cancer: Current evidence and future directions. Thoracic Cancer, 2012, 3, 99-108.	1.9	2
177	Stereotactic ablative radiotherapy: what's in a name?. Practical Radiation Oncology, 2011, 1, 38-39.	2.1	53
178	Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers. Cancers, 2011, 3, 1232-1252.	3.7	52
179	Proton therapy in clinical practice. Chinese Journal of Cancer, 2011, 30, 315-326.	4.9	56
180	Adaptive Radiation for Lung Cancer. Journal of Oncology, 2011, 2011, 1-10.	1.3	28

#	Article	IF	Citations
181	Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer, 2011, 117, 3004-3013.	4.1	117
182	Phase 2 study of highâ€dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer, 2011, 117, 4707-4713.	4.1	157
183	Proton Stereotactic Body Radiation Therapy for Clinically Challenging Cases of Centrally and Superiorly Located Stage I Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1015-1022.	0.8	117
184	Obesity Increases the Risk of Chest Wall Pain From Thoracic Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, 91-96.	0.8	92
185	Toxicity and Patterns of Failure of Adaptive/Ablative Proton Therapy for Early-Stage, Medically Inoperable Nonâ€“Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1350-1357.	0.8	82
186	Implementation of Feedback-Guided Voluntary Breath-Hold Gating for Cone Beam CT-Based Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 80, 909-917.	0.8	50
187	Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team. Cancers, 2011, 3, 3432-3448.	3.7	2
188	Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges. Journal of Thoracic Disease, 2011, 3, 144-6.	1.4	3
189	Evaluation of Tumor Position and PTV Margins Using Image Guidance and Respiratory Gating. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1578-1585.	0.8	24
190	Improving Radiation Conformality in the Treatment of Nonâ€“Small-Cell Lung Cancer. Seminars in Radiation Oncology, 2010, 20, 171-177.	2.2	64
191	Intensity-Modulated Proton Therapy Reduces the Dose to Normal Tissue Compared With Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual Clinical Study. International Journal of Radiation Oncology Biology Physics, 2010, 77, 357-366.	0.8	249
192	Stereotactic Body Radiation Therapy for Patients With Lung Cancer Previously Treated With Thoracic Radiation. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1387-1393.	0.8	151
193	Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer. PLoS ONE, 2010, 5, e12402.	2.5	91
194	Cancer of the Lung. Medical Radiology, 2010, , 755-775.	0.1	0
195	Esophageal cancer: diagnosis and management. Chinese Journal of Cancer, 2010, 29, 843-854.	4.9	24
196	Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. Radiation Oncology, 2009, 4, 4.	2.7	76
197	Consequences of Anatomic Changes and Respiratory Motion on Radiation Dose Distributions in Conformal Radiotherapy for Locally Advanced Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 73, 94-102.	0.8	47
198	Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. Journal of Applied Clinical Medical Physics, 2009, 10, 14-21.	1.9	87

#	Article	IF	Citations
199	Stereotactic Body Radiation Therapy in Centrally and Superiorly Located Stage I or Isolated Recurrent Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 967-971.	0.8	251
200	Effects of Interfractional Motion and Anatomic Changes on Proton Therapy Dose Distribution in Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1385-1395.	0.8	81
201	Treatment of Radioresistant Stem-Like Esophageal Cancer Cells by an Apoptotic Gene-Armed, Telomerase-Specific Oncolytic Adenovirus. Clinical Cancer Research, 2008, 14, 2813-2823.	7.0	96
202	Imageâ€“Guided Radiation Therapy for Nonâ€“small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 177-186.	1.1	101
203	A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. Journal of Applied Clinical Medical Physics, 2008, 9, 110-122.	1.9	5
204	Stereotactic Body Radiation Therapy for Stage I Nonâ€“Small Cell Lung Cancer. Thoracic Surgery Clinics, 2007, 17, 251-259.	1.0	36
205	PD4-1-6: Acute esophageal reactions from proton beam therapy and concurrent chemotherapy for non-small cell lung cancer (NSCLS): Reduction in incidence and severity despite higher doses. Journal of Thoracic Oncology, 2007, 2, S449.	1.1	8
206	4D Proton treatment planning strategy for mobile lung tumors. International Journal of Radiation Oncology Biology Physics, 2007, 67, 906-914.	0.8	178
207	Assessing Respiration-Induced Tumor Motion and Internal Target Volume Using Four-Dimensional Computed Tomography for Radiotherapy of Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 531-540.	0.8	306
208	Assessment of Gross Tumor Volume Regression and Motion Changes During Radiotherapy for Nonâ€“Small-Cell Lung Cancer as Measured by Four-Dimensional Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1036-1046.	0.8	162
209	Comparison of Conformity Index In 3D-CRT, IMRT, and Proton Therapy in Lung Cancer: In Reply to Dr. Armstrong. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1272.	0.8	1
210	Intrathoracic Patterns of Failure for Nonâ€“Small-Cell Lung CancerÂWith Positron-Emission Tomography/Computed Tomographyâ€“Defined Target Delineation. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1409-1416.	0.8	36
211	Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1482-1494.	0.8	13
212	Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III nonâ€“small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1087-1096.	0.8	290
213	Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II nonâ€“small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 117-125.	0.8	285
214	The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. Journal of Nuclear Medicine, 2006, 47, 1756-62.	5.0	72
215	Surgical patterns of care in operable lung carcinoma treated with radiation. Journal of Thoracic Oncology, 2006, 1, 526-31.	1.1	0
216	Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Current Oncology Reports, 2005, 7, 255-259.	4.0	33

#	Article	IF	Citations
217	Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6657-6668.	7.0	39
218	High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Nonâ€“Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy. Clinical Cancer Research, 2005, 11, 2894-2898.	7.0	10
219	Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiotherapy and Oncology, 2005, 77, 247-253.	0.6	150
220	Validation of an accelerated â€˜demonsâ€™ algorithm for deformable image registration in radiation therapy. Physics in Medicine and Biology, 2005, 50, 2887-2905.	3.0	537
221	Telomerase: A potential molecular marker and therapeutic target for cancer. Journal of Surgical Oncology, 2004, 87, 1-3.	1.7	8
222	Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage nonâ€“small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1258-1267.	0.8	249